Patents Assigned to Sanofi
  • Patent number: 11517678
    Abstract: A stopper is disclosed herein. The stopper is configured to be disposed within a medical cartridge. The stopper includes a shell defining a cavity, a core arranged within the cavity, and at least one electronic device embedded within the core, wherein the at least one electronic device includes a sensor and wherein the shell is configured to pass a sensing signal therethrough.
    Type: Grant
    Filed: May 2, 2018
    Date of Patent: December 6, 2022
    Assignee: Sanofi
    Inventors: Michael Schabbach, Alexander Allerdings, Christoph Dette, Martin Otten, Christian Pommereau, Dietmar Hammen, Paul Edward Jansen, Ulrich Brueggemann
  • Patent number: 11518988
    Abstract: The present invention relates to polypeptide variants of porcine trypsin, to nucleic acid molecules encoding these variants, and to host cells comprising such nucleic acid molecules. It also relates to the use of these variants in methods for producing insulin. The invention further relates to the use of these variants as medicaments, as food ingredients, or as feed ingredients and to the use of these variants within a process of manufacturing a food ingredient or a feed ingredient.
    Type: Grant
    Filed: February 22, 2019
    Date of Patent: December 6, 2022
    Assignee: SANOFI-AVENTIS DEUTSCHLAND GMBH
    Inventors: Thomas Stillger, Sebastian Rissom, Claudia Feller, Andreas Vogel
  • Patent number: 11517224
    Abstract: Implantable device for measuring the glucose concentration of a body fluid when implanted, the implantable device comprising a glucose measurement unit, the glucose measurement unit comprising a first light source configured to emit light towards a light transmissive part of a housing of the device and a first optical sensor configured to detect light returned through the light transmissive part from the first light source, and output a first electrical signal based on the detected light; and a wireless communication module configured to wirelessly communicate with an external wireless communication device, wherein the wireless communication module is configured to wirelessly transmit a signal based on the first electrical signal to the external wireless communication device.
    Type: Grant
    Filed: November 15, 2018
    Date of Patent: December 6, 2022
    Assignee: Sanofi
    Inventor: Thomas Klemm
  • Patent number: 11517680
    Abstract: An injection device for setting and injecting of a dose of a medicament includes: an acoustic feedback arrangement comprising: a first feedback element having a first engaging section and having a free end section located at a predetermined distance from the first engaging section, a second feedback element having a second engaging section configured to engage with the first engaging section, wherein the first feedback element is movable, pivotable or resiliently deformable along a first direction (d1) relative to the second feedback element from an initial state (i) towards a biased state (b), and a sound generator formed by the first engaging section or audibly engageable with the free end section of the first feedback element.
    Type: Grant
    Filed: March 12, 2018
    Date of Patent: December 6, 2022
    Assignee: Sanofi
    Inventors: Axel Teucher, Michael Jugl, Stefan Blancke
  • Patent number: 11511043
    Abstract: Described is a syringe carrier comprising a body adapted to receive a barrel of a syringe. The body includes two sections having distal ends with shoulder sections. The shoulder sections are adapted to engage a circumferential gap between the barrel of the syringe and a needle shield covering a needle of the syringe.
    Type: Grant
    Filed: July 21, 2021
    Date of Patent: November 29, 2022
    Assignee: Sanofi-Aventis Deutschland GMBH
    Inventors: Yannick Hourmand, Douglas Ivan Jennings, Matthew Ekman
  • Patent number: 11511047
    Abstract: A data collection device comprises: a first portion having one or more features configured for attaching of the first portion to a dosage knob of an injection device; a second portion rotatably coupled with the first portion, wherein at least part of the second portion is movable axially relative to the first portion; a sensor arrangement configured to detect rotation of the first portion relative to the second portion; and a processor arrangement configured to, based on said detected movement, determine a medicament amount expelled by the injection device, wherein the coupling arrangement is configured to provide a non-permanent coupling between the first portion and the dosage knob of the injection device.
    Type: Grant
    Filed: September 16, 2021
    Date of Patent: November 29, 2022
    Assignee: Sanofi-Aventis Deutschland GMBH
    Inventors: Maurice Toporek, Matthias Felber, Christoph Matthias Gugl, Marcus-Meinolf Dittrich, Christian Nessel, Stephan Riedel, Armin Koller, Alexander Heinrich, Florian Eberli, Philipp Muller, Sven Zwicker
  • Patent number: 11512898
    Abstract: A heating device (124) for heating particles to be freeze-dried in a rotary drum (102) of a freeze-dryer (100) is provided, the device comprising at least one radiation emitter (202) for applying radiation heat to the particles, and a tube-shaped separator (204) for separating the particles from the at least one emitter (202), The separator (202) being integrally closed at one end and separating an emitter volume (206) encompassing the at least one emitter (202) from a drum process volume (126) inside the drum (102), wherein the heating device (124) protrudes into the drum process volume (126) such that said integrally closed end of the separator (204) is arranged inside the drum (102) as a free end.
    Type: Grant
    Filed: October 16, 2019
    Date of Patent: November 29, 2022
    Assignee: Sanofi Pasteur SA
    Inventors: Thomas Gebhard, Roland Kaiser, Matthias Plitzko, Manfred Struschka, Bernhard Luy
  • Patent number: 11511048
    Abstract: The present disclosure relates to a drug delivery device for setting and injecting of a dose of an injectable medicament, the drug delivery device comprising: an elongated housing extending along a longitudinal axis and having a sidewall with at least a first aperture, at least one number sleeve rotatably supported inside the housing and comprising an outer surface, wherein a first portion of the outer surface is visible through the first aperture and wherein the number sleeve comprises a non-visible code in the region of the first portion.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: November 29, 2022
    Assignee: Sanofi-Aventis Deutschland GMBH
    Inventors: Thomas Klemm, Alexander Allerdings, Markus Ploch
  • Publication number: 20220372063
    Abstract: The present disclosure relates to double-stranded oligonucleotides, including double-stranded oligonucleotides such as siRNAs, comprising a sense strand oligonucleotide and an antisense strand oligonucleotide, and wherein the antisense strand oligonucleotide comprises one or more nucleotide analogs of formula (I-A) which are neither the 5?-overhang nucleotide nor the 3?-overhang nucleotide of the said antisense strand oligonucleotide, and wherein a nucleotide analog of formula (I-A) is as described in the disclosure. Oligonucleotides containing these analogs have superior biological activity, for example, increased in vitro stability and improved in vivo potency especially improved off-target profiles. The improved oligonucleotides are useful for silencing (e.g., reducing or eradicating) the expression of a target gene.
    Type: Application
    Filed: September 4, 2020
    Publication date: November 24, 2022
    Applicant: SANOFI
    Inventors: Bodo BRUNNER, Armin HOFMEISTER, Kerstin JAHN-HOFMANN
  • Publication number: 20220372128
    Abstract: The present technology aims at providing a novel type of drug. Specifically, the present technology provides polypeptides comprising at least three immunoglobulin single variable domains (ISVDs), characterized in that at least one ISVD binds to TNF? and at least two ISVDs bind to IL-23. The present technology also provides nucleic acids, vectors and compositions.
    Type: Application
    Filed: April 25, 2022
    Publication date: November 24, 2022
    Applicants: Ablynx N.V., Sanofi
    Inventors: Heidi Rommelaere, Christian Asbrand, Ann Brigé, Sigrid Cornelis, Eric Lorent
  • Patent number: 11504473
    Abstract: A mixing and/or reconstitution system reduces the possibility of user error and provides a well mixed and/or reconstituted drug in a short time. The system comprises a device containing a first material within a first chamber, a housing, and a plunger, the plunger comprising a second chamber containing a second material, wherein one of the first and the second material is a fluid, and a movable element with an electric, magnetic, or paramagnetic characteristic, wherein the second chamber is initially closed; and a base unit comprising a recess for accommodation of the device, a control unit, and an electromagnetic unit which is adapted to produce an electromagnetic field penetrating the recess, wherein the control unit can electrically operate the electromagnetic unit such that the element contained in the second chamber moves in a direction of the device determined by the electromagnetic field and fluidly communicates the first and second chambers.
    Type: Grant
    Filed: November 15, 2018
    Date of Patent: November 22, 2022
    Assignees: Sanofi, Sagentia Ltd.
    Inventors: Michael Schabbach, Dieter Kadereit, Andrea Heiberger, Claus Geiger, Charlotte Emma Harvey, Congyi Huang, Timothy Charles Frearson, Alexander David Norman
  • Patent number: 11504426
    Abstract: Methods for enhancing the efficacy, safety, and/or tolerability of a grass allergen-specific subcutaneous immunotherapy (SCIT) regimen in a subject having a grass allergy are provided. Methods comprising administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody or antigen-binding fragment thereof, are provided.
    Type: Grant
    Filed: August 5, 2020
    Date of Patent: November 22, 2022
    Assignees: REGENERON PHARMACEUTICALS, INC., SANOFI BIOTECHNOLOGY
    Inventors: Jennifer D. Hamilton, Meagan P. O'Brien, Allen Radin, Marcella Ruddy, Heribert Staudinger
  • Patent number: 11504475
    Abstract: Auto-injector for administering a dose of a liquid medicament includes a housing to contain a syringe with a hollow needle and a stopper for sealing the syringe and displacing the medicament, the housing having a distal end and a proximal end with an orifice to apply against an injection site. A spring means, upon activation, can push the needle from inside the housing through the orifice and past the proximal end, operate the syringe to supply the dose of medicament, and retract the syringe with the needle after delivering the medicament. An activating means can lock the spring means in a pressurized state prior to manual operation and capable of, upon manual operation, releasing the spring means for injection.
    Type: Grant
    Filed: July 1, 2022
    Date of Patent: November 22, 2022
    Assignee: Sanofi-Aventis Deutschland GMBH
    Inventors: Matthew Ekman, Yannick Hourmand, Timothy Donald Barrow-Williams
  • Patent number: 11504478
    Abstract: The present specification relates to a subassembly for a drug delivery device, the subassembly comprising: a housing adapted to contain a drug container with a needle, a cap, and a spacer, wherein the housing has an inner surface forming a cavity configured to retain the drug container, wherein the cap is configured to be releasably connected to the housing, and wherein the spacer is arranged between the cap and the housing.
    Type: Grant
    Filed: October 29, 2018
    Date of Patent: November 22, 2022
    Assignee: Sanofi
    Inventor: Thomas Mark Kemp
  • Publication number: 20220362248
    Abstract: Herein are provided a combination of palbociclib and of 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing such a combination, and the therapeutic uses thereof, in particular for the treatment of cancer, including breast cancer.
    Type: Application
    Filed: January 19, 2022
    Publication date: November 17, 2022
    Applicant: SANOFI
    Inventors: Monsif BOUABOULA, Maysoun SHOMALI, Fangxian SUN
  • Publication number: 20220363747
    Abstract: The present technology aims at providing a novel type of drug. Specifically, the present technology provides polypeptides comprising at least three immunoglobulin single variable domains (ISVDs), characterized in that at least one ISVD binds to TNF? and at least two ISVDs bind to IL-23. The present technology also provides nucleic acids, vectors and compositions.
    Type: Application
    Filed: April 25, 2022
    Publication date: November 17, 2022
    Applicants: Ablynx N.V., Sanofi
    Inventors: Heidi Rommelaere, Christian Asbrand, Ann Brigé, Sigrid Cornelis, Eric Lorent
  • Patent number: 11499777
    Abstract: The present invention provides, inter alia, for a liquid feeding device for the generation of droplets, in particular for the use in a process line for the production of freeze-dried particles, with a droplet ejection section for ejecting liquid droplets in an ejection direction, the droplet ejection section comprising at least one inlet port for receiving a liquid to be ejected, a liquid chamber for retaining the liquid, and a nozzle for ejecting the liquid from the liquid chamber to form droplets, wherein the liquid chamber is restricted by a membrane on one side thereof, the membrane being vibratable by an excitation unit, wherein the longitudinal axis of the liquid chamber is tilted relative to the longitudinal axis of the nozzle, and/or the liquid feeding device further comprises a deflection section for separating the droplets from each other by means of at least one gas jet, wherein the deflection section gas jet intersects perpendicular with an ejection path of the liquid ejected from the liquid chamb
    Type: Grant
    Filed: January 8, 2020
    Date of Patent: November 15, 2022
    Assignee: Sanofi Pasteur SA
    Inventors: Thomas Gebhard, Roland Kaiser, Bernhard Luy, Matthias Plitzko, Manfred Struschka, Christian Zerillo
  • Patent number: 11497854
    Abstract: A system comprises a first member, a second member, and a third member, wherein the first and second members are rotatable relative to the third member, wherein the first and second members are coupled to one another by a dead-angle follower coupling, wherein the dead-angle follower coupling is configured such that the first and second members are rotatable relative to one another, wherein the second and third members are rotationally coupled to one another by a switchable coupling mechanism, wherein the switchable coupling mechanism is switchable between two different states, a locked state and a non-locked state, wherein the maximum torque transferable between the second and third members via the switchable coupling mechanism in the locked state is greater than in the non-locked state, wherein the switchable coupling mechanism is in the locked state when the first member is in a locking position relative to the second member.
    Type: Grant
    Filed: November 27, 2018
    Date of Patent: November 15, 2022
    Assignee: Sanofi
    Inventors: Ralph Donald Quentin Collings, James Robert Coop, James Anthony West, Stephen Francis Gilmore, Daniel David Higgins, Mark Digby Teucher, Stefan Blancke
  • Patent number: 11498969
    Abstract: The present disclosure provides compositions and methods of treating and improving the symptoms of systemic juvenile idiopathic arthritis and polyarticular-course juvenile idiopathic arthritis using an antibody that specifically binds human interleukin-6 receptor (hIL-6R).
    Type: Grant
    Filed: January 31, 2020
    Date of Patent: November 15, 2022
    Assignees: SANOFI BIOTECHNOLOGY, REGENERON PHARMACEUTICALS, INC.
    Inventors: Lydie Baret-Cormel, Tanya Momtahen, Stefano Fiore, Janet Van Adelsberg
  • Publication number: 20220356241
    Abstract: The present disclosure provides a novel type of drug for treating a subject suffering from an inflammatory and/or autoimmune disease, and specifically rheumatoid arthritis. Specifically, the disclosure provides polypeptides comprising at least three immunoglobulin single variable domains (ISVDs), characterized in that at least one ISVD binds to TNF-? and at least two ISVDs bind to IL-6. The present disclosure also provides nucleic acids, vectors and compositions.
    Type: Application
    Filed: December 17, 2021
    Publication date: November 10, 2022
    Applicants: Ablynx N.V., Sanofi
    Inventors: Heidi Rommelaere, Christian Asbrand, Nadine Biesemann, Ann Brigé, Sigrid Cornelis, Karen Heyninck, Eric Lorent, Shanna Van Zwam